Home Banner

Thank you for your interest in the ENLIVEN study.

Additional enrollment of the ENLIVEN study in Tenosynovial Giant Cell Tumor (TGCT) has been discontinued. However the study will proceed with currently enrolled patients under a revised protocol.

For more information, please click on this link to the press release issued by Daiichi Sankyo.


About TGCT-

Tenosynovial giant cell tumor (or TGCT) is a rare disease in which tumors grow in the tissue surrounding the joint area.* There are 2 broad types of TGCT, localized and diffuse. Localized TGCT, also known as giant cell tumor of the tendon sheath (GCT-TS), usually affects the hand, wrist, ankle, and/or foot. Diffuse TGCT generally impacts larger joints and is also known as pigmented villonodular synovitis (PVNS). 75% of diffuse TGCT cases involve the knee. The growing tumor and inflammation can cause pain and swelling, and greatly impact mobility. A common treatment is surgical removal of the lesion, but this may not relieve all of the symptoms associated with TGCT. Also, TGCT has about a 15%-45% chance of coming back, depending on form and location.


Tenosynovial giant cell tumor (TGCT) includes pigmented villonodular synovitis (PVNS) and giant cell tumor of the tendon sheath (GCT-TS).